Literature DB >> 29104036

Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride.

Lei Zhang1, Chao Chen2, Nan Zhou3, Yuming Fu4, Xingbo Cheng5.   

Abstract

BACKGROUND: Asprosin has been identified as a novel hormone enriched in white adipose tissue and is pathologically increased in insulin-resistant mice and humans. However, information regarding the role of asprosin in type 2 diabetes mellitus (T2DM) remains unavailable. Via conducting a hospital-based study, we purposed to ascertain the potential relationship between circulating asprosin concentrations and T2DM.
METHODS: The study recruited 84 adults with T2DM and 86 controls with normal glucose tolerance. They matched in age, body mass index (BMI), and sex. Serum asprosin concentrations were measured via ELISA method.
RESULTS: Compared to the controls, serum asprosin concentrations were significantly increased in the T2DM adults (P<0.001). As asprosin concentrations increased across its tertiles, the percentage of T2DM increased (39.28, 37.50, and 70.68%; P value for trend <0.001). Multivariate logistic regression models demonstrated that compared with the 1st tertile of asprosin, the odds ratio of T2DM was 3.278(95% CI 1.053-10.200, P=0.040) for the 3rd tertile after adjustment for potential confounders. Area under ROC curve of asprosin (sex and age adjusted) for predicting the presence of T2DM was 0.707[95% CI 0.628-0.786]. Finally, multiple stepwise regression analysis indicated that fasting glucose and triglyceride were independently associated with serum asprosin in T2DM.
CONCLUSIONS: Asprosin concentrations are increased in adults with T2DM. The results suggest that asprosin might serve as a risk factor associated with the pathogenesis of T2DM, but not an ideal biomarker for predicting T2DM.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adipokine; Asprosin; Insulin resistance; Type 2 diabetes mellitus; White adipose tissue

Mesh:

Substances:

Year:  2017        PMID: 29104036     DOI: 10.1016/j.cca.2017.10.034

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  39 in total

1.  Increased plasma asprosin levels in patients with drug-naive anorexia nervosa.

Authors:  Yanran Hu; Yixiang Xu; Yuchen Zheng; Qing Kang; Zhongze Lou; Qiang Liu; Han Chen; Yunxin Ji; Lei Guo; Chen Chen; Liemin Ruan; Jue Chen
Journal:  Eat Weight Disord       Date:  2020-02-05       Impact factor: 4.652

2.  Higher Serum Asprosin Level is Associated with Urinary Albumin Excretion and Renal Function in Type 2 Diabetes.

Authors:  Xia Deng; Li Zhao; Chang Guo; Ling Yang; Dong Wang; Yanyan Li; Hong Xia; Chenxi Wang; Zhensheng Cai; Lian Li; Zhicong Zhao; Guoyue Yuan
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-13       Impact factor: 3.168

Review 3.  Caudamins, a new subclass of protein hormones.

Authors:  Bijoya Basu; Mahim Jain; Atul R Chopra
Journal:  Trends Endocrinol Metab       Date:  2021-10-16       Impact factor: 12.015

4.  Levels of circulating GRP78 and CHOP in endoplasmic reticulum stress pathways in Chinese type 2 diabetic kidney disease patients.

Authors:  Ning Ma; Ning Xu; Dong Yin; Ping Zheng; Weiwei Liu; Guofeng Wang; Yuan Hui; Guanjun Han; Chuanhui Yang; Xingbo Cheng
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

Review 5.  Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the FBN1 Gene, in Health and Disease.

Authors:  Mehmet Akif Ovali; Ibrahim Bozgeyik
Journal:  Mol Syndromol       Date:  2022-02-08

6.  Association of cord blood asprosin concentration with atherogenic lipid profile and anthropometric indices.

Authors:  Hanan Khudhair Hussein; Nassrin Malik Aubead; Hamzah H Kzar; Yasir Salam Karim; Ali H Amin; Moaed E Al-Gazally; Tousief Irshad Ahmed; Mohammed Abed Jawad; Ali Thaeer Hammid; Abduladheem Turki Jalil; Yasser Fakri Mustafa; Marwan Mahmood Saleh; Hafez Heydari
Journal:  Diabetol Metab Syndr       Date:  2022-05-18       Impact factor: 5.395

7.  Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy.

Authors:  Golnoosh Goodarzi; Leila Setayesh; Reza Fadaei; Mohammad Ebrahim Khamseh; Fereshteh Aliakbari; Jalil Hosseini; Nariman Moradi
Journal:  Mol Biol Rep       Date:  2021-07-25       Impact factor: 2.316

Review 8.  Energy Regulation Mechanism and Therapeutic Potential of Asprosin.

Authors:  Jennifer G Hoffmann; Wei Xie; Atul R Chopra
Journal:  Diabetes       Date:  2020-04       Impact factor: 9.461

9.  [Expression, purification and functional assessment of asprosin inclusion body].

Authors:  Xuejing Wei; Qingqing Ao; Ling Meng; Yilu Xu; Cailing Lu; Shen Tang; Xinhang Wang; Xiyi Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-01-30

10.  Ameliorative Effect of Oxytocin on FBN1 and PEPCK Gene Expression, and Behavioral Patterns in Rats' Obesity-Induced Diabetes.

Authors:  Asmaa Elnagar; Khalifa El-Dawy; Hussein I El-Belbasi; Ibrahim F Rehan; Hamdy Embark; Zeinab Al-Amgad; Obeid Shanab; Elsayed Mickdam; Gaber E Batiha; Salman Alamery; Samer S Fouad; Simona Cavalu; Mohammed Youssef
Journal:  Front Public Health       Date:  2022-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.